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Abstract
Background: Central sensitization is a potential severe consequence of invasive surgical procedures. It results in
postoperative and potentially chronic pain enhancement. It results in postoperative pain enhancement; clinically
manifested as hyperalgesia and allodynia. N-methyl-D-aspartate (NMDA) receptor plays a crucial role in the
mechanism of central sensitisation. Ketamine is most commonly used NMDA-antagonist in human and veterinary
practice. However, the antinociceptive serum concentration of ketamine is not yet properly established in dogs.
Six dogs were used in a crossover design, with one week washout period. Treatments consisted of: 1) 0.5 mg/kg
ketamine followed by continuous rate infusion (CRI) of 30 μg/kg/min; 2) 0.5 mg/kg ketamine followed by CRI of
30 μg/kg/min and lidocaine (2 mg/kg followed by CRI of 100 μg/kg/min); and 3) 0.5 mg/kg ketamine followed by
CRI of 50 μg/kg/min. The infusion was administered up to 120 min. Nociceptive thresholds and ketamine serum
concentrations were measured before drug administration, and at 5, 10, 20, 40, 60, 90, 120, 140 and 160 min after
the start of infusion.
Results: Maximum concentration recorded was 435.34 ± 26.18 ng/mL, 582.34 ± 227.46 ng/mL and 733.77 ± 133.
6 ng/mL for K30, KL30 and K50, respectively. The concentration at 120 min was 250.87 ± 39.87, 221.73 ± 91.03 and
343.67 ± 63.21 ng/mL at 120 min in K30, KL30 and K50, respectively. All the three infusion regimes maintained
serum concentrations above 200 ng/mL. The thresholds returned towards baseline values within 20 min, after
cessation of infusion.
Conclusion: Serum concentration to produce mechanical antinociceptive effects in dogs is between 100 and
200 ng/mL. All the three infusion regimes in this study provided antinociceptive effects throughout the infusions.
In this study, we found that the serum concentration of ketamine to produce mechanical antinociceptive effects
in dogs is above 200 ng/mL. All three infusion regimes provided antinociceptive effects throughout the infusions
without causing harmful effects. Further studies are recommended in a clinical setting.
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Background
The glutamate-activated N-methyl-D-aspartate (NMDA)
receptor plays a crucial role in the development of cen-
tral sensitization. Some of the characteristics associated
with central sensitization are manifested clinically by a
painful sensation from a non-painful stimulus (allodynia)
and augmented pain sensation from previously painful
stimuli (hyperalgesia) [1–5].
Association of the NMDA receptor with postoperative
pain ushered a new chapter in the exploration of
NMDA-antagonists for postoperative analgesia protocol.
Ketamine is well established NMDA- antagonist. It is
commonly used as an anaesthetic agent in children and
animals. It is useful for its anti-nociceptive properties in
acute pain, and can be used for chronic and neuropathic
pain as well [4]. Ketamine has prevented hyperalgesia,
improved analgesia [6–8] and decreased postoperative
opioid consumption [8–10] in surgical patients.
The analgesic dose range of ketamine for use in dogs
has not been properly established. As a consequence, an-
algesic benefits of ketamine are not yet fully recognized
in dogs. The effective dose range of ketamine in human
surgical patients has been established at a loading dose
of 0.5 mg/kg, followed by continuous rate infusion (CRI)
of 2 to10 μg/kg/min [7, 10–12]. In the absence of ap-
propriate analgesic dose range, the doses used in studies
of dogs [13–15] have been taken from human studies
[16, 17]. This has resulted in reporting inconclusive
results. Moreover, most of the studies were clinical.
Consequently, the use of opioids pre and postopera-
tively in these studies might have masked the analgesic ef-
fects of ketamine. Apart from this, various scoring scales
used in these studies have not been validated for reliability,
specificity or linearity. Most importantly these scales were
based on subjective assessment of behaviour [18, 19],
which can be biased by inter-observer variability. Further-
more, none of these studies correlated effects with serum
concentrations of ketamine.
So far, only one study reported plasma concentration
versus antinociceptive actions in dogs [20]. In this study,
ketamine was administered at 0.5 mg/kg, followed by
10 μg/kg/min for 59 min in dogs, antinociceptive effect
was demonstrated only for the first four minutes, at which
time the plasma concentration was >100 ng/mL. Plasma
concentration of ketamine declined to <100 ng/mL after
5 min [20]. Further analysis revealed that the plasma con-
centrations of ketamine at pseudo-steady state were five
times lower than the expected concentrations to that in
humans receiving the same CRI. They concluded that
this dose was insufficient to maintain the analgesic con-
centration of the ketamine. This also suggests that keta-
mine pharmacokinetics in dogs may differ from that in
humans, and that may warrant the use of higher infu-
sion rates in dogs.
Lidocaine is commonly used as a local anaesthetic and
anti-arrhythmic agent in veterinary and human medi-
cine. With the mechanism based approach combination
of lidocaine acting on sodium channels, which play a
part in generation and transmission of nociceptive im-
pulses [1] and ketamine acting on NMDA receptors
would be better strategy to manage postoperative pain,
compared to conventional method of administering sin-
gle drug for post operative pain management. The major
benefit of combining lidocaine and ketamine is to pre-
vent the development of central sensitization during
surgical intervention [21], which may reduce pain and
discomfort in the postoperative period. The combination
of ketamine and lidocaine has been reported to decrease
the minimum alveolar concentration (MAC) of inhalant
anaesthetics in dogs [22–25]. It has been suggested that
the MAC reducing effect may be due to analgesic or
sedative effect or both [22, 24, 25]. The analgesic effects
of the combination of lidocaine and ketamine in con-
scious dogs have not been reported.
This study therefore, aimed to correlate the serum
concentrations of ketamine to the antinociceptive effects
using two infusion rates of ketamine. Furthermore, this
study also evaluated the clinical and antinociceptive ef-
fects of incorporation of lidocaine infusion to ketamine
in a controlled, repeatable situation.
Methods
Animals and treatments
Six adult healthy mix-breed female dogs weighing 17.2 ±
2.2 kg (Mean ± SD) with the age of 2 to 10 years old
were used in this study. Animals were obtained from a
local stray animal holding facility following informed con-
sent. These animals were acclimatized for one month,
during this period they were kept under observation for
any disease or abnormality. Dogs were judged healthy
based on physical examination, hematology, and blood
biochemistry, and have not been showing any sign of ill-
ness during one month of previous observation. Animals
were brought daily to the experimental room, which was
adjacent to the kennels, in order to familiarise them with
the experimental station. Experiments were conducted in
animal experimental station in a quiet environment with
minimum number of observers. Experiments were con-
ducted in day time, starting at 8:00 am. The study was
approved by the Universiti Putra Malaysia Animal Care
and Utility Committee (Reference Number UPM/IACUC/
AUP-R023/2013).
All six dogs were subjected to three treatment proto-
cols in a randomized crossover design with one-week
washout period between the treatments. Treatment pro-
tocols were: 1) 0.5 mg/kg ketamine (NARKETAN®-10,
100 mg/mL, Vetoquinol UK Limited, Buckingham, UK)
followed by continuous rate infusion (CRI) of 30 μg/kg/
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min (K30); 2) Combination of ketamine (0.5 mg/kg
followed by CRI of 30 μg/kg/min) and lidocaine hydro-
chloride (Xylocaine® 2 % AstraZeneca, France) 2 mg/kg
followed by CRI of 100 μg/kg/min (KL30); and 3) 0.5 mg/
kg ketamine followed by CRI of 50 μg/kg/min (K50).
The loading doses of K30, KL30 and K50 were mixed in
normal saline to a final volume of 3 mL and injected over
one minute. Ketamine was diluted with normal saline to
5 mg/mL and lidocaine 16.66 mg/mL for infusion. Infu-
sions were delivered for 120 min through a precision syr-
inge pump (Omnifuse, Graseby medical limited, United
Kingdom). Right and left cephalic veins were catheterized
with 20 G indwelling catheters (Vasofix® Braunule®, B.
Braune Melsungen AG 34209 Melsungen, Germany) for
blood sampling and infusion of drugs, respectively. Prior
to the actual study, the infusion regimens were tested in
two of the six dogs.
Algometer device
Wagner algometer (FPX 25, Wagner Instruments,
Greenwich CT, USA) with a modified tip was used in
this study.
Nociceptive mechanical thresholds
The nociceptive mechanical thresholds were recorded in
duplicates from the carpal pad, metacarpal footpad, tibia
and femur of right limbs, and the abdomen. Thresholds
were determined before treatment as baseline and then
after start of treatment at 10, 20, 40, 60, 90, 120, 140
and 160 min. These body points were selected based on
models used in the previous studies [26–28] conducted
in dogs. The carpal pad and metacarpal pad were tested
by applying the tip of the algometer at midpoint of these
pads. The tibia was tested on the distal latero-dorsal sur-
face where bone could be palpated through the skin.
The femur was tested on the distal latero-dorsal surface,
where the bone could be palpated through the skin by
displacing the muscle with little pressure applied with
fingers. The abdomen was tested on the midline at the
midpoint between umbilicus and pubis. The order of
testing was firstly the metacarpal pad, followed by carpal
pad, femur, tibia, and finally, the abdomen. At each test-
ing point, the tip was placed perpendicular to the surface
area. The pressure was increased gradually until the dog
responded. The entire threshold recording was per-
formed by the same researcher. During thresholds
determination, the operator did not look at the reading
of the algometer as he applied consistent force. Instead,
he concentrated on the dogs’ response and immediately
stopped at response. The end-points were cross-checked
by another observer who took note of both the alg-
ometer readings and dogs’ response. The most common
response identified during the preliminary trial was clear
withdrawal reflex of the limb, vocalization, withdrawal of
the limb accompanied with vocalization and guarding of
the abdomen. According to Le Bars et al. (2001), in
order to avoid tissue damage, cut-off pressure should be
set at three times the thresholds of control [29]. Prelim-
inary trials and the baseline thresholds on body points
tested in this study were 5 to 6 Newtons (N). Thus, the
cut-off pressure was set at 18 N for this study. If no re-
action was perceived before the cut-off limit, this value
(18 N) was recorded as the mechanical nociceptive
threshold. One of the dogs did not respond to applica-
tion of the algometer up to the cut-off point of 18 N at
its abdomen, thus, was not tested at abdomen for all
treatment groups.
Sedation score and side effects
A composite sedation score and a behavioural chart
adopted from Bergadano et al. (2009) were used to
evaluate the psychomimetic side effects of ketamine at
the measurement time points [20]. The sedation score
on a 0 (no sedation) to 12 (deep sedation) scale, was
assigned by adding the ranking of different descriptors
(Table 1). The incidence of psychomimetic signs (dis-
orientation, lateral head movements, fixed eyes, apneus-
tic respiration, salivation, tremors and hyperactivity) was
noted for each treatment group. The person involved in
scoring sedation and side effects was blinded to the
treatments.
Blood sampling
Blood samples were taken before administration of treat-
ment as baseline, and then at 1, 5, 10, 20, 40, 60, 90, 120
and 140 min after the start of infusion. At each time
points, 2 mL of blood was sampled and kept in plain
sampling tubes (BD Vacutainer®, BD Franklin Lakes NJ
USA), and immediately placed on ice. Samples were
centrifuged and serum was harvested, and then frozen at
- 80 °C until analysis.
Table 1 Sedation score scale used in this system (Adopted from Bergadano et al. 2009)
Score Consciousness Eye Responsiveness Relaxation
0 Awake Not rotated Respond to voice Moves spontaneously
1 Aware Moderate rotation Respond to gentle touch Relaxed, no shivering
2 Not aware but arousable Rotated Does not respond to touch Very Relaxed
3 Not aware and not arousable Nystagmus Hyperexcitable Hypertonous
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High performance liquid chromatography analysis
Ketamine concentration in serum was determined using
high performance liquid chromatography (HPLC). In
brief, the system consisted of Waters HPLC 2695 separ-
ation module, an Agilent C18 column (5 μm particle size;
4.6 × 150 mm), photodiode array (PDA) detector and a
computer equipped with Empower software (Waters,
Milford, MA, USA).
Extraction of drug from serum
The ketamine was extracted from serum by the method
reported earlier (Doherty et al. 2007). Briefly, the frozen
serum samples were thawed followed by vortex mixing
and transferred to 1 mL of glass test tube containing
25 μL of (internal standard, 50 μg/mL) trimethoprim.
Further, 200 μL of 1 molar solution (1 M) of sodium hy-
droxide (NaOH) and 5 mL methylene chloride (CH2Cl2)
were added to above samples. Tubes were vortex mixed
again and then centrifuged for 20 min at 1500 g. The
organic layer was separated and placed in clean tube
evaporated with gentle stream of nitrogen till dryness.
Finally, samples were reconstituted with 1 mL of mobile
phase and 100 μL was injected for HPLC analysis.
Sample analysis
In brief, freshly prepared isocratic mixture of 0.02 M po-
tassium dihydrogen phosphate (KH2PO4) pH 4.5, ad-
justed with phosphoric acid and acetonitrile (ACN)
(ACN:KH2PO4 (40:60) was used as mobile phase with
flow rate of 1.0 mL/min. Calibration curves for serum
analysis were prepared by spiking the dog serum with
ketamine. A linear concentration range of 25–1500 ng/mL
was established with r2 value of 0.99.
Statistical analysis
Data are presented as mean ± standard deviation. Statis-
tical analysis was performed using the SAS software
package, version 9.3 (SAS Institute Inc., Cary, NC, USA).
Prior to the analysis, data were checked for their con-
formance to the normal distribution using Kolmogrov-
Simirnov test. Changes in mechanical thresholds and
serum concentrations over time and across treatment
groups were compared using the repeated-measures
ANOVA model. Bonferroni adjusted P values were used
when indicated by a significant F test (P < 0.05). Correl-
ation between the mechanical thresholds and serum
concentrations of ketamine was calculated with Pearson
test. Effects of treatment over time on sedation score
were analyzed using Friedman’s test. Overall significance
was set at a value of P < 0.05. The observed power for the
current study was determined to be 80.53 % for 1-Way
ANOVA, and 90.75 % for Repeated Measure ANOVA.
This was based on an effect size value of 0.8165, obtained
by calculating the serum ketamine concentrations 1 min
after administration (peak value), and at 120 min after ad-
ministration. Power calculations were performed using
G*Power Software, version 3.1.9.2 [30].
Results
The experiments were well tolerated by all the dogs.
Changes in behavior due to recognized psychomimetic
effects of ketamine were mild and harmless. The behav-
ioral changes disappeared within 20 min after the end of
infusion, and the dogs resumed their activity immedi-
ately after the end of experiment. The algometer device
was well tolerated by all the animals. Transient dimples
were observed at the carpal pad, metacarpal footpad,
and abdomen, which disappeared within 1 min, before
the replicate measurement. There was no sign of red-
ness, swelling, bleeding, exudates, and lameness during,
immediately after, and 24 h after the experiment.
Serum concentrations of ketamine
The serum concentrations (Mean ± SD) of K30, KL30
and K50 across time points are illustrated in Fig. 1. Max-
imum concentration was observed at 1 min for K30
(435.34 ± 26.18 ng/mL), KL30 (582.34 ± 227.46 ng/mL),
and K50 (733.77 ± 133.6 ng/mL), which remained stable
for 20 min, and declined gradually reaching around
250.87 ± 39.87, 221.73 ± 91.03 and 343.67 ± 63.21 ng/mL
at 120th min in K30, KL30 and K50, respectively. The
serum concentration decreased rapidly to less than
100 ng/mL within 20 min following the end of infusions
in all three treatments. Between 1 and 40 min, serum
concentration of K50 was higher than K30, while con-
centration of KL30 lied in between K50 and K30. By
60th min, the three groups were not statistically
different.
Fig. 1 Comparison (Mean ± SD) between serum concentration of K30,
KL30 and K50 in 6 dogs during and after CRI. K30 = Ketamine 0.5 mg/
kg loading dose followed by 30 μg/kg/min, KL30 = Ketamine 0.5 mg/
kg loading dose followed by 30 μg/kg/min and lidocaine 2 mg/kg
loading dose followed by 100 μg/kg/min, K50 = Ketamine 0.5 mg/kg
loading dose followed by 50 μg/kg/min CRI. At each time point,
groups with similar alphabet are not different (P < 0.05)
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Nociceptive mechanical thresholds
There was no significant difference among the baseline
mechanical thresholds at carpal pad, metacarpal foot
pad, tibia, femur and abdomen in all treatment groups
(Fig. 2a-e). All the three treatments increased thresholds
significantly (P < 0.05) throughout the infusion up to
120 min. Mechanical thresholds returned to baseline
within 20 min of the end of CRI at 140th min. Overall,
nociceptive mechanical thresholds were higher in KL30
than in K30 and also higher in K50 than in KL30, and
some significant differences between groups were
recorded. There was weak positive correlation between
serum concentration of K30 with mechanical thresh-
olds at carpal pad (r-0.24 P = 0.141), metacarpal foot-
pad (r-0.32, P = 0.053), tibia (r-0.33, P = 0.047), femur
(r-0.30, P = 0.075) and abdomen (r-0.35, P = 0.053). Like-
wise, weak positive correlation of K50 with mechanical
thresholds at carpal pad (r-0.29 P = 0.080), metacarpal
footpad (r-0.38, P = 0.020), tibia (r-0.18, P = 0.330), femur
(r-0.22, P = 0.185) and abdomen (r-0.12, P = 0.527) were
observed.
Heart rate, body temperature and respiration
Baseline heart rates were not different amongst all treat-
ments. Heart rates increased significantly from baselines
in all treatments during the 120 min of treatment infu-
sions. Following cessation of infusions, heart rates de-
creased, but remained higher than baselines in KL30 and
K50. Heart rates between K30 and KL30 were not differ-
ent, while K50 resulted in higher heart rates compared
to K30 at 40 to 60 min and KL30 at 40 to 120 min
(Table 2). Body temperatures increased significantly
from baselines throughout the 160-minute study period
in K30 and KL30 groups, and up to 120 min in K50
(Table 3). This increase in body temperature was within the
normal range. The change in respiration was insignificant
in K30, while KL30 and K50 resulted in increased respira-
tory rates at 120 to 160, and 20 to 160 min, respectively.
Fig. 2 Effects of K30, KL30 and K50 on mechanical nociceptive thresholds measured at the carpal pad (a), metacarpal footpad (b), tibia (c), femur
(d) (n = 6) and abdomen (e) (n = 5). K30 = Ketamine 0.5 mg/kg loading dose followed by 30 μg/kg/min CRI, KL30 = Ketamine 0.5 mg/kg loading
dose followed by 30 μg/kg/min and lidocaine hydrochloride 2 mg/kg loading dose followed by 100 μg/kg/min CRI, K50 = Ketamine 0.5 mg/kg
loading dose followed by 50 μg/kg/min CRI,. Data are expressed as mean ± SD. * denotes significant difference from baseline within treatment, at
each time point, groups with similar alphabet are not different (P < 0.05)
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Respiratory rate increased from 33 ± 7 at baseline, to as
much as 93 ± 5 breaths per minute in KL30, and from 29 ±
7 at baseline, to as much as 93 ± 5 breaths per minute in
K50 during infusion of treatment.
Sedation and side effects
Sedation score and side effects are presented in Tables 4
and 5. There was significant difference in the sedation
score between K30, KL30 and K50 groups. The median
sedation scores were 0 throughout the 160-minute study
period in K30 and KL30. In contrast, median score in
K50 were 3 between 1 and 20 min, and reduced to 1 be-
tween 40 and 90 min. Most of the dogs exhibited one or
more side effects such as disorientation, swaying of the
head, salivation and hyperactivity. These effects were ob-
served throughout the duration of 120 min infusion and
disappeared at 140th min, which is within 20 min after
the end of infusions. The side effects were less severe in
K30 and KL30 compared to K50.
Discussion
The concentrations of ketamine in the present study were
435.34 ± 26.18 ng/mL for K30, 582.34 ± 227.46 ng/mL for
KL30 and 733.77 ± 133.6 ng/mL for K50 at 1 min and
250.87 ± 39.87, 221.73 ± 91.03 and 343.67 ± 63.21 ng/mL
at 120 min for K30, KL30 and K50, respectively. The
serum concentrations of ketamine produced by all the 3
CRI regimens in this study could be maintained above
100 ng/mL during the 120- min infusions. Furthermore,
nociceptive thresholds at most body points were raised
above baseline values during the 120 min of infusions.
The nociceptive thresholds returned towards baseline
values within 20 min after cessation of infusions, at which
point, serum levels were found to be lower than 100 ng/
mL. Results from this study suggested that the minimum
concentration of ketamine to produce analgesia in dogs is
between 100 as observed at 140 min and 200 ng/mL dur-
ing infusion. This concurred with findings in humans,
where serum concentration of 100–200 ng/mL of keta-
mine was reported to be analgesic with minimal side
effects [11, 31].
Effective analgesic concentration of ketamine has not
been reported in dogs. The only study reporting the an-
algesic concentration of ketamine versus its antinocicep-
tive action in dogs has been conducted by Bergadano et
al. [20]. They found that the analgesic effect only lasted
for the first four minutes at plasma concentration of
220–370 ng/ mL. No further analgesic effect was ob-
served thereafter for up to 59 min, when plasma concen-
tration was found to be below 100 ng/mL. They selected
Table 2 Effects of K30, KL30 and K50 on heart rates (Mean ± SD)
measured in 6 dogs using crossover design
K30 KL30 K50
Baseline 79 ± 6 77 ± 7 81 ± 6
20 min 113 ± 24a 101 ± 19a 113 ± 22a
40 min 104 ± 16a 99 ± 18a 123 ± 19abc
60 min 105 ± 15a 104 ± 260a 124 ± 23abc
90 min 113 ± 15a 107 ± 21a 127 ± 25ac
120 min 106 ± 19a 98 ± 20a 114 ± 14ac
140 min 93 ± 20 93 ± 12a 99 ± 15a
160 min 86 ± 14 94 ± 11a 102 ± 25ab
K30 Ketamine 0.5 mg/kg loading dose followed by 30 μg/kg/min CRI, KL30
Ketamine 0.5 mg/kg loading dose followed by 30 μg/kg/min and lidocaine
hydrochloride 2 mg/kg loading dose followed by 100 μg/kg/min CRI, K50 0.5 mg/kg
loading dose followed by 50 μg/kg/min CRI. adenotes significant difference from
baseline within same treatment, bdenotes significant difference from K30 at
corresponding values, cdenotes significantly different from KL30 at corresponding
time points. Overall significance was set at a value of P< 0.05
Table 3 Effects of K30, KL30 and K50 on body temperatures
(Mean ± SD) measured in 6 dogs using crossover design
K30 KL30 K50
Baseline 38.6 ± 0.4 38.7 ± 0.3 38.8 ± 0.2
20 min 39.0 ± 0.5a 39.1 ± 0.6a 39.2 ± 0.6a
40 min 39.1 ± 0.6a 39.0 ± 0.5a 39.3 ± 0.5a
60 min 39.2 ± 0.4a 39.1 ± 0.4a 39.3 ± 0.5a
90 min 39.2 ± 0.4a 39.1 ± 0.4a 39.0 ± 0.4a
120 min 39.1 ± 0.5a 39.1 ± 0.5a 39.0 ± 0.3a
140 min 39.3 ± 0.5a 39.2 ± 0.4a 39.0 ± 0.3
160 min 39.0 ± 0.4a 39.1 ± 0.5a 39.0 ± 0.3
K30 Ketamine 0.5 mg/kg loading dose followed by 30 μg/kg/min CRI, KL30
Ketamine 0.5 mg/kg loading dose followed by 30 μg/kg/min and lidocaine
hydrochloride 2 mg/kg loading dose followed by 100 μg/kg/min CRI, K50
0.5 mg/kg loading dose followed by 50 μg/kg/min CRI adenotes significant
difference from baseline within same treatment. Overall significance was set at
a value of P < 0.05
Table 4 Sedation score in median (IQR) values across each time
points of the each group after administration of K30, K50, and
KL30 in 6 dogs
Time (minutes) K30 KL30 K50a
0 0 (0–0) 0 (0–0) 0 (0–0)
01 0 (0–0) 0 (0–0) 3 (0–3)
05 0 (0–0) 0 (0–0) 3 (0–3)
20 0 (0–0) 0 (0–0) 3 (0–3)
40 0 (0–0) 0 (0–0) 1 (0–3)
60 0 (0–0) 0 (0–0) 1 (0–3)
90 0 (0–0) 0 (0–0) 1 (0–3)
120 0 (0–0) 0 (0–0) 0 (0–0)
140 0 (0–0) 0 (0–0) 0 (0–0)
160 0 (0–0) 0 (0–0) 0 (0–0)
K30 ketamine 0.5 mg/kg loading dose followed by 30 μg/kg/min, K50 0.5 mg/kg
loading dose followed by 50 μg/kg/min, KL = ketamine 0.5 loading dose followed
by 30 μg/kg/min + lidocaine 2 mg/kg loading dose followed by 100 μg/kg/min.
Overall significance was set at a value of P < 0.05. aK50 is significantly different
from K30 and KL at P < 0.003 (Friedman test)
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a ketamine dose of 0.5 mg/kg and 10 μg/kg/min from
the human studies [16, 17, 31, 32]. However, these dos-
ages had difficulties to sustain a desired plasma ketamine
concentration (i.e. above 100–200 ng/mL) to produce
antinociceptive effect conscious dogs. The authors sug-
gested that this variation was due the difference in
pharmacokinetics of ketamine between human and dogs,
in addition to inter-species an intra species difference
has also been reported in dogs [33]. Various factors
could contribute to the individual variations within the
species; these include age, body weight, lean-to-fat body
ratio and genetics [34–36]. Although there is no data
reporting the influence of genetic factors on the dispos-
ition of ketamine in dogs, its potential role cannot be ex-
cluded. In this study, we selected the ketamine dose
based on the prior results reported by Bergadano et al.
[20] . We used similar loading dose of 0.5 mg/kg, but in-
creased the CRI to 30 and 50 μg/kg/min, doses 3 and 5
times higher than that used by Bergadano. Both the
doses maintained serum concentration above the level
required to raise the mechanical nociceptive thresholds
up to 120 min. Our study showed that the mechanical
nociceptive threshold in dogs can be raised through
ketamine infusion. In order to maintain this plasma
concentration and have an antinociceptive effect over
120 min, higher infusions rates than previously
employed by Bergadano et al. in dogs (20) are deemed
necessary. A time of 120 min was selected in our study
to simulate a multimodal analgesic approach that could
provide pre-intra and post-operative antinociception for
a potential surgery of 45 min. This period covers the
time before, during and after surgery up to recovery.
Thus, results of this study confirmed the need for higher
infusion rates of ketamine in dogs than that previously
employed by Bergadano in dogs [20].
In the present study, the concentration of ketamine
was higher during first 10–20 min of adminsitration,
and declined gradually thereafter. The initial hike and
maintenance of the higher serum concentrations were
likely contributed by the loading dose. Since ketamine
is a high clearance drug, it requires continuous infu-
sion for at least five half lives, which is approximately
10 h to maintain steady state [37]. Ketamine also in-
creases sympathetic nervous system activity, resulting
in increased cardiovascular functions and hepatic
blood flow [38, 39]. Thus, the elevated heart rates in
the present study are likely a reflection of sympathetic
stimulation by ketamine.
Table 5 Frequency of side effects (number of dogs out of six showing a specific psychomimetic sign)
0 min 1 min 5 min 20 min 40 min 60 min 90 min 120 min 140 min 160 min
Disorientation/confused K30 0 5 5 4 3 3 3 3 0 0
K50 0 5 5 6 6 6 5 6 0 0
KL30 0 4 5 5 5 5 5 5 0 0
Lateral head movements K30 0 3 3 2 2 2 2 2 0 0
K50 0 5 5 6 6 6 5 5 0 0
KL30 0 3 4 4 4 4 4 4 0 0
Glazy Eyes K30 0 0 0 0 0 0 0 0 0 0
K50 0 0 0 0 0 0 0 0 0 0
KL30 0 0 0 0 0 0 0 0 0 0
Apneustic respiration K30 0 0 0 0 0 0 0 0 0 0
K50 0 0 0 0 0 0 0 0 0 0
KL30 0 0 0 0 0 0 0 0 0 0
Salivation K30 0 4 4 4 4 4 4 4 0 0
K50 0 4 4 4 4 4 4 4 0 0
KL30 0 4 4 4 4 4 4 4 4 0
Tremors K30 0 0 0 0 0 0 0 0 0 0
K50 0 0 0 0 0 0 0 0 0 0
KL30 0 0 0 0 0 0 0 0 0 0
Hyperactivity K30 0 1 1 1 1 1 1 1 0 0
K50 0 3 3 3 3 3 3 3 0 0
KL30 0 2 2 2 1 1 0 0 0 0
K30 ketamine 0.5 mg/kg loading dose followed by 30 μg/kg/min, K50 0.5 mg/kg loading dose followed by 50 μg/kg/min, KL30 ketamine 0.5 loading dose
followed by 30 μg/kg/min + lidocaine 2 mg/kg loading dose followed by 100 μg/kg/min
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Nociceptive mechanical thresholds increased signifi-
cantly compared to baseline after administration of the
K30, KL30 and K50 groups and remained elevated
throughout the 120-minutes of infusion. The thresholds
returned to baseline at 140 min, that is, within 20 min
after the end of infusion. Mechanical thresholds have been
used in previous studies in animals [14, 26–28, 40–45] for
the objective quantification of pain and to evaluate the an-
algesic efficacy of drugs. The analgesic effect of the test
drug reported by these studies was either increase in the
mechanical thresholds at the site of test compared to
baseline [26, 28] or concurrent rise in the mechanical
thresholds equal to that produced by positive control anal-
gesic or dose used to compare with [40, 45] or equal rise
in mechanical thresholds at the site of surgery by the same
drug compared for two routes of administration [40, 44].
Kukanich et al. (2005) and Kaka et al. (2015) reported in-
crease in mechanical thresholds after administration of
intravenous morphine at 1 mg/kg [26, 28]. The increase in
mechanical thresholds compared to baseline in these stud-
ies was suggestive of analgesic action of morphine. In the
present study mechanical thresholds increased signifi-
cantly compared to baseline in K30, KL30 and K50 treat-
ments throughout the infusion period of 120 min and
returned to baseline within 20 min after the end of infu-
sion. The rise in mechanical thresholds suggests the anti-
nociceptive actions of K30, KL30 and K50 throughout the
duration of infusion. The modified algometer and tech-
nique used in this study have been validated previously in
our lab [28]. In this study, conscious vocalization may not
be a good indicator of nociceptive threshold as it occurred
only in 2 of subjects, and therefore we depended on alg-
ometer readings, even though vocalization has been ac-
cepted as part of the pain study protocol in human beings.
Mechanical pressure for quantification of surgical pain
or hyperalgesia is termed as “algometry”. Algometry has
been used to identify abnormal pain thresholds and to
monitor response to analgesic treatment in animals and
humans [46–49]. Algometry has also been used to evalu-
ate the analgesic effects of drugs in dogs [26, 27, 40].
Rate of force of application plays a crucial part on the
reliability of this method. Application of force at a faster
rate may provoke a low false threshold reading [50]. In a
study of reliability and validity of algometer Kinser et al.
(2009) concluded that this is highly reliable and valid
method [51]. The authors suggested that with some
practice, an individual becomes reliable in applying force
with an algometer. In this study researcher who operated
the algometer has sufficient practice in applying the rate
of force of application during preliminary experiments,
which have been demonstrated as consistent results in
saline treatment during validation of the method [28].
Similarly, in this study no significant difference in mech-
anical thresholds between control and 140 min indicates
the reliability of results. Thus, the results of the above
studies suggest that algometry is reliable and valid tech-
nique for the quantification of mechanical nociceptive
thresholds. It should be noted that despite an open label
approach of the current study, potential operator bias
was minimized by blinding the operator of the algometer
to the threshold values. Only another nearby observer
who was not operating the algometer was entrusted to
record the readings displayed on the LCD screen. It
should be noted that the operator of the algometer, can-
not see the values projected on the LCD screen. We are
aware that open label studies have the limitation that re-
sults could be refined and biased [51], however, we tried
to minimise the bias by blinding to the treatment the in-
vestigator who evaluated sedation and side effects of the
infusions, and the investigator operating the algometer
to the values recorded.
Ketamine has been reported to increase body temperature
in dogs [23]. Effects of body temperature on mechanical
thresholds in dogs have not been reported. In this study
body temperatures increased significantly from baseline
throughout study, however, this increase was within the nor-
mal range. The increase in mechanical thresholds through-
out infusion and decrease in the mechanical thresholds after
the end of infusion, at which time the temperature was still
higher than baseline suggests that increase in temperatures
did not affect the mechanical thresholds.
Ketamine is well known for its psychomimetic effects
in dogs; these effects range from hypersalivation to excit-
ability and delirium. The dose regimens used in this
study did produce such side effects; however they were
harmless and ceased within 20 min of ending the infu-
sions. Furthermore, side effects were less intense and oc-
curred less frequently in K30 and KL30 compared to
K50. The sedation score recorded in this study was as
low as 0 in K30 and KL30, and as high as 3 in K50,
which is mild and comparable to the scores reported by
Bergadano et al. [20].
Commonly used potent analgesics reduce the mini-
mum alveolar concentration (MAC) of inhalant anaes-
thetics in dogs and humans [52, 53] ; the reduction in
MAC of inhalant anaesthetic has been suggested either
due to analgesic or sedative effects of the drug. Hence, if
a drug decreases the MAC, it should be tested for its an-
algesic effects in awake patients [54]. The dosage of lido-
caine selected in this study was based on MAC studies
in dogs under anaesthesia [25] and studies in conscious
dogs [55]. In the study on conscious dogs, lidocaine CRI
of 100 μg/kg/min up to four hours did not produce any
side effect [55]. Therefore, lidocaine at 2 mg/kg loading
dose and CRI 100 μg/kg/min was combined to ketamine
in this study. This combination of lidocaine and keta-
mine in present study was tested in preliminary study on
two dogs before actual experiments. The major benefit
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of combining lidocaine and ketamine is to decrease the
drug related side effects [56], decrease opioid require-
ment [57] intensity of pain in postoperative period due
to central sensitization during surgical intervention [21].
The addition of lidocaine at 2 mg/kg loading dose and
CRI of 100 μg/kg/min to ketamine infusion in this study
resulted in higher mean nociceptive threshold values
only at carpal pad and metacarpal footpad. Whereas, no
difference in the serum concentration between K30 and
KL 30 as well as KL 30 and K50 was observed due to
addition of lidocaine to ketamine. The inherent high in-
dividual variability in these parameters would require
large sample size to demonstrate statistical difference,
which was not feasible in this study.
In this study, overall nociceptive thresholds were rela-
tively higher in K50 than K30. Suggesting that K50 pro-
vided slightly more analgesia than K30. On the other
hand, there was no such difference between KL30 and
K50. Thus, K 50 and KL30 demonstrated more or less
similar effect on nociceptive thresholds than K30. Never-
theless, all the three regimens significantly raised noci-
ceptive thresholds from baseline thresholds, suggesting
significant analgesic effects demonstrated by the three
regimens used. Further studies are required to investi-
gate the analgesic effects of these three doses in dogs
undergoing surgical procedures.
Conclusions
All the three treatment regimes in this study maintained
serum concentrations of ketamine above 200 ng/mL and
raised mechanical nociceptive thresholds at most body
points during the 120 min of infusions. A linear correl-
ation between the mechanical thresholds and serum con-
centrations of ketamine was found. Results from this
study suggested that the minimum concentration of keta-
mine to produce analgesia in dogs is between 100 and
200 ng/mL. All the three treatments provided antinoci-
ceptive effects throughout the infusions. In this setting the
addition of lidocaine to ketamine increased mechanical
thresholds without any further side effect. Clinical studies
are encouraged to evaluate the analgesic effects of keta-
mine CRI and combination of lidocaine and ketamine at
these dose regimens.
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